17 Comments

Boy, must they hate the Japanese now. Especially for their pricing.

Expand full comment
23 hrs agoLiked by James Lyons-Weiler

Maybe those whose bodies have become spike protein factories through repeated jabs would benefit from a course of treatment with this?

Expand full comment

Pineapple better. No jabs, but I just ate mine!

Expand full comment

Forgive my ignorance- but where can I learn more about how we are measuring viral load in such discussions?

Expand full comment

Hard pass!

Expand full comment

Ensitrelvir looks to me to have plenty of covalent bonds. Linus Pauling rolls over in his grave!

Expand full comment

The FDA will be working hard to find a reason this shouldn't be used, while the media will stop people hearing about it as long as possible, and then tell everyone why it's dangerous.

Expand full comment

I do not take new experimental drugs especially for colds I already have natural immunity to. But it might be helpful for the elderly or immune compromised? If they don’t mind being a Guinea pig…again

Expand full comment
18 hrs ago·edited 18 hrs ago

> achieving an approximately 30-fold reduction (bringing the viral load to 1/300 of its baseline level)

This is *extremely* misleading -- primarily because PLACEBO results in the reduction of the viral load as well.

From Phase 2A publication (https://pmc.ncbi.nlm.nih.gov/articles/PMC9578433/):

"The change from baseline in viral RNA level (log10 copies/mL) on day 4 was significantly greater in the ensitrelvir 125 mg (mean [SD], –2.677 [1.063]; difference from placebo, –1.408; P = 0.0029) and 250 mg (–2.761 [1.291]; difference from placebo, –1.492; P = 0.0039) groups versus the placebo group (–1.269 [1.228])."

Thus, we have the following results.

From BASELINE:

Dose-------------|----------Viral Titer (fraction)----------|----Viral Titer Fold Change

125 mg----------|----------0.0021------------------------|----------476

250 mg----------|----------0.0017------------------------|----------588

From PLACEBO:

Dose-------------|----------Viral Titer (fraction)---------|----Viral Titer Fold Change

125 mg----------|----------0.039------------------------|----------26

250 mg----------|----------0.032------------------------|----------31

That having been said, in Phase 2B, the Viral Titer fraction compared to placebo is only 0.39, and thus the fold change from placebo is *only 2.5 times*.

All that having been said, while PLACEBO (i.e., the immune system) results in very similar reduction of the viral load as well, it happens much slower, which ultimately produces the key benefit for the severely ill: quick reduction of the viral load.

This is the primary niche for these pharmaceutical products.

Expand full comment

2.5 times lower aint chump change imo If you think the virus floating around is not a good thing

Expand full comment

2.5 times is also not 30 times and not 300 times, eh?

My entire point is that the original statement by JLW is misleading as fuck.

Expand full comment

oh to be sure. what, you think this isnt some pharma company?

Expand full comment

I'm puzzled by JLW's praise. It *seems* to be a decent product, but is it definitely safe and definitely efficacious? Knowing what we know now, I think it's too early to tell.

Expand full comment

Hi James, Have you found anything on Defluorination of Ensitrelvir inside or outside Humans?

https://en.wikipedia.org/wiki/Ensitrelvir

Expand full comment

Big issue with Pax is rebound. what do we know about reboud with this? IMO, they should dose twice a long

Expand full comment

Question: Had medicine wanted to develop lots of preperatory antivirals for covid before covid even existed, how successful would they have been? I would think extremely so. I suppose a related way of framing the question is: if medicine sanely went about trying to cure the common cold, would it not have done so 20 different ways by now?

Expand full comment